Lycia Therapeutics Targets 938M Valuation in US IPO
Drug developer Lycia Therapeutics aims for a valuation up to 938 million dollars in its US initial public offering. The firm seeks to raise 265 million dollars by offering shares priced between 16 and 18 dollars.
Xurve View
Insights:
Xurve View
Drug developer Lycia Therapeutics is targeting a valuation of up to $937.7 million in a United States IPO. The offering aims to raise up to $264.6 million through 14.7 million shares priced between $16 and $18.
